United Kingdom (UK)
Recombinant monoclonal antibody to ZIKV E domain III. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the B-cell clone SMZAb1.
UniProt Accession Number of Target Protein: Q91KX7
Alternative Name(s) of Target: ZEDIII
Immunogen: Antibody genes were cloned from blood-derived plasmablasts of a ZIKV-infected human subject from Colombia in the acute phase. Amplified heavy and light chains were tested for neutralisation, and SMZAb1 was selected from this.
Specificity: SMZAb1 binds to domain III of the ZIKV E protein.
Application Notes: ELISA was used to confirm SMZAb1 binds to the ZIKV E domain, and neutralisation assays identified the IC50 of SMZAb1 as 5.4 ng/ml. Four macaques were injected with a cocktail of anti-Zika antibodies (SMZAb1, SMZAb2, SMZAb5) and then infected with ZIKV virus. The antibody cocktail appeared to confer sterilising immunity on the treated macaques and completely prevented viral replication, which was not seen with the control group (Magnani et al, 2017).
Antibody first published in:
Magnani et al, 2017. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques Sci Transl Med. 2017 Oct 4;9(410). pii: eaan8184 PMID:28978754
Note on publication:
Describes the isolation of SMZAb1, its characterisation through ELISA and neutralisation assays, and its efficacy in preventing ZIKV viral replication.